PixarBio NeuroRelease A Non-Addictive, Non-Opiate Morphine Replacement™
PixarBio CEO Frank Reynolds Executive Interview
PixarBio CEO/CSO Frank Reynolds Discusses His 60 US-INTL Neurological Patent Filings from 2006-2017
Knee Surgery Pain Treatment
Shoulder Surgery Pain Treatments
Hip Surgery Pain Treatments
Back Pain – Facet Joint
Non-Opiate Post-Operative, Acute & Chronic Pain System
One year after hip, knee and spine surgeries, 80% of patients report that pain is moderate to severe after surgery. Pain limits the patient’s physical therapy outcome and thereby reduces the possibility of a full recovery.
NanoMedicines and Microparticles
Nanoscale Delivery Systems and Microparticles provide new biomaterials platform opportunities for targeted drug delivery. PixarBio is using patent pending formulations of FDA approved biomaterials and FDA approved non-opiate drugs to target key neurological areas to treat pain.
PixarBio cofounder Frank Reynolds has an in-depth knowledge of the needs of the postsurgical pain, acute pain and chronic pain markets. Frank’s passion for delivering improved quality of life for all neurological patients drives PixarBio’s commitment to concurrently engineer new treatments for a wide range of painful conditions. We believe that these treatments may reduce drug addiction associated with opiate pain killers and improve clinical outcomes.
Our founders’ expertise in cGMP manufacturing of biomaterials with extensive safety records and a history of FDA regulatory approvals has given PixarBio the insight in-house on how to reach those goals by applying our core competencies to developing new treatment options for doctors and patients.
With our team’s expertise on over 60 products approved by the FDA to start human studies, we have unmatched experience in the drug delivery system space and a track record of successfully developing FDA approved products.